Receptor Downregulator(受体下调剂)研究综述
Receptor Downregulator 受体下调剂 - At present, hormone therapy is still the main treatment route and can be divided into three main categories: selective estrogen receptor modulators (SERMs), selective estrogen receptor downregulators (SERDs), and aromatase inhibitors (AIs). [1] Possible strategies to overcome this resistance by using selective estrogen receptor downregulators (such as fulvestrant) are also discussed. [2] Standard therapies for treating hormone-sensitive metastatic breast cancer (BC) include the blockage of estrogen pathways by using selective estrogen modulator receptors or selective estrogen receptor downregulators and by using aromatase inhibitors to block estrogen production. [3] Selective estrogen receptor downregulators and immune checkpoint inhibitors in breast cancer immunotherapy [abstract]. [4] Purpose Fulvestrant is a selective estrogen receptor downregulator (SERD) that is approved for first- or second-line use as a single agent or in combination with cyclin dependent kinase or phosphatidylinositol 3-kinase inhibitors for the treatment of metastatic breast cancer. [5] AEs, depending on the mechanism of action, are classified as either selective estrogen receptor modulators (SERMs), which display tamoxifen-like partial agonism, or as selective estrogen receptor downregulators (SERDs) that confer structurally induced posttranslational modifications (PTMs) that destine these receptors for proteosomal degradation. [6] selective estrogen receptor downregulator (SERD), might be an effective alternative to hormone therapy for breast cancer. [7] The resistance to the endocrine therapy of breast cancer leads to the emergence of new class of drugs that downregulates the estrogen receptor action known as selective estrogen receptor downregulators (SERDs). [8]目前，激素治疗仍是主要治疗途径，可分为三大类：选择性雌激素受体调节剂（SERMs）、选择性雌激素受体下调剂（SERDs）和芳香化酶抑制剂（AIs）。 [1] 还讨论了通过使用选择性雌激素受体下调剂（如氟维司群）来克服这种耐药性的可能策略。 [2] 治疗激素敏感性转移性乳腺癌 (BC) 的标准疗法包括通过使用选择性雌激素调节剂受体或选择性雌激素受体下调剂以及通过使用芳香酶抑制剂来阻断雌激素产生来阻断雌激素途径。 [3] 乳腺癌免疫治疗中的选择性雌激素受体下调剂和免疫检查点抑制剂[摘要]。 [4] 用途 Fulvestrant 是一种选择性雌激素受体下调剂 (SERD)，被批准作为单药或与细胞周期蛋白依赖性激酶或磷脂酰肌醇 3-激酶抑制剂联合用于治疗转移性乳腺癌的一线或二线药物。 [5] AEs，取决于作用机制，分为显示他莫昔芬样部分激动作用的选择性雌激素受体调节剂 (SERM)，或赋予结构诱导的翻译后修饰 (PTM) 的选择性雌激素受体下调剂 (SERD)蛋白质体降解的受体。 [6] 选择性雌激素受体下调剂（SERD）可能是乳腺癌激素治疗的有效替代方案。 [7] 对乳腺癌内分泌治疗的耐药性导致了新型药物的出现，这些药物可以下调雌激素受体的作用，称为选择性雌激素受体下调剂 (SERD)。 [8]
Estrogen Receptor Downregulator 雌激素受体下调剂
At present, hormone therapy is still the main treatment route and can be divided into three main categories: selective estrogen receptor modulators (SERMs), selective estrogen receptor downregulators (SERDs), and aromatase inhibitors (AIs). [1] Possible strategies to overcome this resistance by using selective estrogen receptor downregulators (such as fulvestrant) are also discussed. [2] Standard therapies for treating hormone-sensitive metastatic breast cancer (BC) include the blockage of estrogen pathways by using selective estrogen modulator receptors or selective estrogen receptor downregulators and by using aromatase inhibitors to block estrogen production. [3] Selective estrogen receptor downregulators and immune checkpoint inhibitors in breast cancer immunotherapy [abstract]. [4] Purpose Fulvestrant is a selective estrogen receptor downregulator (SERD) that is approved for first- or second-line use as a single agent or in combination with cyclin dependent kinase or phosphatidylinositol 3-kinase inhibitors for the treatment of metastatic breast cancer. [5] AEs, depending on the mechanism of action, are classified as either selective estrogen receptor modulators (SERMs), which display tamoxifen-like partial agonism, or as selective estrogen receptor downregulators (SERDs) that confer structurally induced posttranslational modifications (PTMs) that destine these receptors for proteosomal degradation. [6] selective estrogen receptor downregulator (SERD), might be an effective alternative to hormone therapy for breast cancer. [7] The resistance to the endocrine therapy of breast cancer leads to the emergence of new class of drugs that downregulates the estrogen receptor action known as selective estrogen receptor downregulators (SERDs). [8]目前，激素治疗仍是主要治疗途径，可分为三大类：选择性雌激素受体调节剂（SERMs）、选择性雌激素受体下调剂（SERDs）和芳香化酶抑制剂（AIs）。 [1] 还讨论了通过使用选择性雌激素受体下调剂（如氟维司群）来克服这种耐药性的可能策略。 [2] 治疗激素敏感性转移性乳腺癌 (BC) 的标准疗法包括通过使用选择性雌激素调节剂受体或选择性雌激素受体下调剂以及通过使用芳香酶抑制剂来阻断雌激素产生来阻断雌激素途径。 [3] 乳腺癌免疫治疗中的选择性雌激素受体下调剂和免疫检查点抑制剂[摘要]。 [4] 用途 Fulvestrant 是一种选择性雌激素受体下调剂 (SERD)，被批准作为单药或与细胞周期蛋白依赖性激酶或磷脂酰肌醇 3-激酶抑制剂联合用于治疗转移性乳腺癌的一线或二线药物。 [5] AEs，取决于作用机制，分为显示他莫昔芬样部分激动作用的选择性雌激素受体调节剂 (SERM)，或赋予结构诱导的翻译后修饰 (PTM) 的选择性雌激素受体下调剂 (SERD)蛋白质体降解的受体。 [6] 选择性雌激素受体下调剂（SERD）可能是乳腺癌激素治疗的有效替代方案。 [7] 对乳腺癌内分泌治疗的耐药性导致了新型药物的出现，这些药物可以下调雌激素受体的作用，称为选择性雌激素受体下调剂 (SERD)。 [8]